IBD SGI Diagnostic Panel
| Label Mnemonic: | IBDSGI |
| Epic code: | LAB3400 |
| Downtime form: | A-1a Doctor/Provider Orders - Pathology Core and Specialty Care Nursery |
Commercial Mailout Laboratory
6240-8 RCP
356-8593
6240-8 RCP
356-8593
Specimen(s):
Serum and EDTA
Collection Medium:
 | and |  |
| Red top tube 5 mL (Clot Activator) | Lavender top tube 3 mL (EDTA) |
Minimum:
2.0 mL serum in red top tube + 2.0 mL whole blood in (EDTA) lavender
top tube. Both tube types are
required.
Turn Around
Time:
3-4 days upon receipt at reference laboratory
Reference Range:
NOTE: Patient test results are based on the Smart Diagnostic Algorithm which interprets patterns among the assay and values. ASCA IgA ELISA: <9.2 EU/mL ASCA IgG ELISA: <11.9 EU/mL Anti-OmpC IgA ELISA: <11.3 EU/mL Anti-CBir1 ELISA: <35.4 EU/mL Anti-A4-Fla2 IgG ELISA: <32.4 EU/mL Anti-FlaX IgG ELISA: <36.0 EU/ml IBD Specific pANCA IFA Perinuclear Pattern: Not Detected IBD Specific pANCA IFA DNAse Sensitivity: Not Detected ATG16L1 SNP (rs2241880): Variant Not Detected EMC1 SNP (rs3737240): Variant Not Detected NKX2-3 (rs10883365): Variant Not Detected STAT3 SNP (rs744166): Variant Detected ICAM-1: <0.52 μg/mL VCAM-1: <0.75 μg/mL VEGF: <393 pg/mL CRP: <13.4 mg/L SAA: <22.9 mg/L
Comments:
This test aids in differentiating IBD vs non-IBD and Crohn's Disease
vs Ulcerative Colitis in one comprehensive blood test.
This assay includes 9 serological markers including the proprietary Anti-Fla-X, Anti-A4-Fla2, Anti-CBir1, Anti-OmpC, and DNAse-sensitive pANCA that helps identify patients with IBD and utilizes Smart Diagnostic Algorithm Technology to improve the predictive accuracy. Genetic susceptibility influences immune responses and this assay includes evaluation of ATG16L1, STAT3, NKX2-3, and ECM1. Inflammatory markers include VEGF, ICAM, VCAM, CRP, SAA. While most other labs only offer assay values, the reference laboratory provides added clarity in diagnosing IBD, UC, and CD.
The reference laboratory services provide important information to aid in the diagnosis and management of certain diseases. Test results should be used with other clinical and diagnostic findings to make a diagnosis and prognosis. This test was developed and its performance characteristics determined by the reference laboratory and has not been cleared or approved by the U.S. Food and Drug Administration.
This assay includes 9 serological markers including the proprietary Anti-Fla-X, Anti-A4-Fla2, Anti-CBir1, Anti-OmpC, and DNAse-sensitive pANCA that helps identify patients with IBD and utilizes Smart Diagnostic Algorithm Technology to improve the predictive accuracy. Genetic susceptibility influences immune responses and this assay includes evaluation of ATG16L1, STAT3, NKX2-3, and ECM1. Inflammatory markers include VEGF, ICAM, VCAM, CRP, SAA. While most other labs only offer assay values, the reference laboratory provides added clarity in diagnosing IBD, UC, and CD.
The reference laboratory services provide important information to aid in the diagnosis and management of certain diseases. Test results should be used with other clinical and diagnostic findings to make a diagnosis and prognosis. This test was developed and its performance characteristics determined by the reference laboratory and has not been cleared or approved by the U.S. Food and Drug Administration.
Methodology:
Enzyme-linked immunosorbent Assays (ELISA) and indirect
immunofluorescent assays
CPT Code:
81479 x4,83520 x6,82397 x4,86140, 88346 x1, 88350 x1